We use essential cookies (authentication, your saved goals/stack) by default. With your permission we’ll also enable privacy-respecting analytics (Vercel Web Analytics, anonymous load-time metrics) and error-replay diagnostics (Sentry — DOM snapshots only when an error fires) so we can fix bugs faster. Learn more about cookies
MitoQ (Mitoquinol Mesylate)
A mitochondria-targeted antioxidant — CoQ10 conjugated to a triphenylphosphonium (TPP+) cation so it accumulates several-hundred-fold inside mitochondria. Sold OTC as a supplement. Its best human signal is improved endothelial/vascular function in older adults (one small RCT); several trials are null (Parkinson's, exercise adaptation), and almost all outcomes are surrogate/biomarker, not hard clinical endpoints.
What the evidence says
MitoQ doesn't have enough studies with structured effect-size data yet to pool a verdict. Browse the studies below for individual findings.
Most evidence is from high-quality meta-analyses and randomised trials published 2010–2026.
Based on 33 studies · 2 meta-analyses · 19 RCTs
Confidence
High confidenceBy outcome
Earns a Moderate 5: a well-characterized mitochondria-targeting mechanism plus a small positive RCT for endothelial function in older adults and supportive vascular pilots, offset by a clearly null landmark Parkinson's trial, null exercise-adaptation data, and the fact that nearly every positive outcome is a surrogate biomarker (FMD, ALT) rather than a hard clinical or lifespan endpoint.
19 randomised trials
95% were about MitoQ in an audit of 19 of them
Every randomised or controlled trial of MitoQ indexed in PubMed, not a hand-picked subset. Meta-analyses and systematic reviews are deliberately excluded from this count: most of them cover many compounds at once, so counting them would inflate it.
PubMed · as of Sep 2026
17 trials ongoing or recruiting · 18 completed on ClinicalTrials.gov
5 of the completed trials have posted results
Registered trials show research momentum for MitoQ, not proof of effect — a registration is a plan, and posted results are sponsor-reported, not peer-reviewed. They are never counted toward the evidence rating above.
Browse these trials on ClinicalTrials.govClinicalTrials.gov · as of Nov 2026
MitoQ is mitoquinol/mitoquinone mesylate — the antioxidant quinone of coenzyme Q10 chemically tethered to a lipophilic triphenylphosphonium (TPP+) cation.
The positive charge drives the molecule across the mitochondrial inner membrane, where it concentrates several-hundred-fold relative to ordinary CoQ10 and is recycled by the respiratory chain back to its active ubiquinol form.
The rationale is that excess mitochondrial reactive-oxygen-species (ROS) production drives age-related vascular dysfunction, so a mitochondria-targeted antioxidant should improve function where untargeted antioxidants fail.
The honest read of the human evidence: the single best signal is a small crossover RCT in healthy older adults (Rossman 2018, Hypertension) where 6 weeks of 20 mg/day raised brachial-artery flow-mediated dilation (a surrogate marker of endothelial function) by ~42%.
Smaller pilot RCTs echo acute or short-term vascular improvements in peripheral artery disease and chronic kidney disease, and a phase-II hepatitis-C trial lowered liver aminotransferases (ALT) without changing viral load.
Against that, the largest and most rigorous clinical trial — the PROTECT study in newly-diagnosed Parkinson's disease (128 patients) — found NO effect on disease progression, and a controlled exercise-training study found MitoQ neither helped nor hurt aerobic adaptations.
So the evidence is genuinely mixed: a plausible, well-characterized mechanism and a few positive surrogate-marker RCTs in vascular function, set against null disease-modifying trials and an absence of any hard clinical-outcome or lifespan data in humans.
It is generally well tolerated at studied doses (10-20 mg/day), making it a reasonable, modest-evidence option for those targeting vascular/mitochondrial support rather than a proven therapy.
A lipophilic triphenylphosphonium cation drives accumulation several-hundred-fold inside mitochondria.
Neutralizes mitochondrial reactive oxygen species (ROS) at their source, regenerated by the respiratory chain.
Reducing mitochondrial ROS improves vascular endothelial function in aging arteries.
How MitoQ works — from molecular targets to health outcomes. Click an edge to see supporting research.This visualization is in beta — pathways are being refined and expanded.
Insufficient safety data; avoid unless directed by a clinician.
The main RCT population (60-79 yr); 20 mg/day was well tolerated over 6 weeks.
Studied in small hepatitis-C and CKD pilots and tolerated, but only short-term; involve the treating clinician.
Possible additive vascular/BP effects given the endothelial-function mechanism; monitor.
As with other CoQ10-related compounds, theoretical interaction with warfarin; monitor INR.
Tip: Generally well tolerated in trials; take with a small amount of food if it occurs.
Tip: If you develop a new or unexpected symptom, pause this optional product and seek advice before trying a lower dose, a different schedule or an added remedy. Follow any urgent instructions for the symptom now.
MitoQ has an evidence score of 5/10 — moderate evidence based on 33 indexed studies. A mitochondria-targeted antioxidant — CoQ10 conjugated to a triphenylphosphonium (TPP+) cation so it accumulates several-hundred-fold inside mitochondria. Sold OTC as a supplement. Its best human signal is improved endothelial/vascular function in older adults (one small RCT); several trials are null (Parkinson's, exercise adaptation), and almost all outcomes are surrogate/biomarker, not hard clinical endpoints. Representative study: PMID 20568096.
The commonly studied dose of MitoQ is 10-20mg daily. Individual needs vary, so check the right dose for you with a healthcare provider.
The best time to take MitoQ is in the morning. It can be taken on an empty stomach. Most human trials dosed MitoQ once daily at 20 mg in the morning on an empty stomach (the manufacturer recommends taking it ~30-60 min before food).
MitoQ is generally well-tolerated and considered safe for most healthy adults at recommended doses. Reported side effects include GI upset / abdominal discomfort, headache. How often they occur is not established for all of them. Use caution if any of these apply to you: None established at studied doses; consult a clinician if pregnant, nursing, or on the medications below.
CoQ10
Likely helpsA lipid-soluble antioxidant central to mitochondrial energy production, with the strongest trial support for fertility/IVF outcomes and heart failure.
Caffeine
Probably helpsBlocks adenosine receptors to boost alertness, reaction time, and endurance — an umbrella review of 21 meta-analyses found it ergogenic for endurance, strength and power.
Red Yeast Rice
Likely helpsFermented rice containing natural statins that effectively lower LDL cholesterol — the original statin.
Berberine
Likely helpsActivates AMPK to regulate blood sugar, improve insulin sensitivity, and support lipid metabolism. Its only head-to-head trial with metformin cited here was a 36-person pilot, which does not show it can replace metformin.
Explore: Best supplements for Vitality & LongevityBest supplements for Focus, Memory & MoodBest supplements for Athletic Performance
Reviewed by Dr. Baher Al Hakim · Last reviewed June 2026 · evidence from 33 studies · how we score · editorial policy
This information is for educational purposes only. It is not a substitute for professional medical advice. Always consult a qualified healthcare provider before starting, stopping, or changing any supplement or medication.
Tap node to isolate • Pinch to zoom • Tap edge for research